|Cat. No. 198 108||50 µg purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.|
WB: 1 : 1000 (AP staining) gallery
IP: not tested yet
ICC: 1 : 500 gallery
IHC: 1 : 500 gallery
IHC-P/FFPE: not tested yet
|Subtype||IgG1 (κ light chain)|
|Immunogen||Recombinant protein corresponding to AA 3 to 96 from mouse GAD2 (UniProt Id: P48320)|
Epitop: AA 3 to 17 from mouse GAD2 (UniProt Id: P48320)
Reacts with: rat (Q05683), mouse (P48320).
Other species not tested yet.
|Specificity||Specific for GAD 2 / GAD 65|
|Matching control protein/peptide||198-1P|
This antibody is a chimeric antibody based on the well known monoclonal mouse antibody clone 26H1D1. The constant regions of the heavy and light chains have been replaced by rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.
The glutamic acid decarboxylases GAD 2, also referred to as GAD 65, and GAD 1 / GAD 67 synthesize γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. The hydrophilic GAD 1 can heterodimerize with the membrane achored GAD 2 and part of GAD 1 is targeted to inhibitory nerve terminals by this mechanisms. Although both proteins exhibit significant differences in their N-terminus they share high homology in the rest of the molecule.
GADs are a widely used markers for the GABAergic system. In type 1 diabetes GAD 1 has been identified as a major autoantigen.